Clinical Chemistry
CHEM-40005
Learn how clinical chemists identify and quantify a variety of analytes in blood and bodily fluids using analytical techniques. This course explores the basic principles, procedures, physiological basis, instrumentation, and significance of testing performed in clinical chemistry. The emphasis is on basic laboratory techniques to assess analytes including electrolytes, proteins, carbohydrates, hormones, hemoglobin, and serum enzymes, and the correlation of test results with diseases and disorders. Statistical techniques, therapeutic drug monitoring, molecular diagnostics, and reference values are also covered.
Course Information
Course sessions
Section ID:
Class type:
This course is entirely web-based and to be completed asynchronously between the published course start and end dates. Synchronous attendance is NOT required.
You will have access to your online course on the published start date OR 1 business day after your enrollment is confirmed if you enroll on or after the published start date.
Textbooks:
Tietz Fundamentals fo Clinical Chemistry and Molecular Diagnostics 8th
by Nader Rifai
ISBN / ASIN: 9780323530446
You may purchase textbooks via the UC San Diego Bookstore.
Policies:
- No refunds after: 1/20/2025
Schedule:
Instructor: Heather Grandin
Section ID:
Class type:
This course is entirely web-based and to be completed asynchronously between the published course start and end dates. Synchronous attendance is NOT required.
You will have access to your online course on the published start date OR 1 business day after your enrollment is confirmed if you enroll on or after the published start date.
Textbooks:
Tietz Fundamentals fo Clinical Chemistry and Molecular Diagnostics 8th
by Nader Rifai
ISBN / ASIN: 9780323530446
You may purchase textbooks via the UC San Diego Bookstore.
Policies:
- No refunds after: 1/20/2025
Schedule:
Instructor:
Mihai Azimioara
Mihai D. Azimioara is currently Senior Staff Scientist in the Chemistry Department at 1859, Inc. in San Diego. He has more than 25 years of experience in drug discovery.
He received his BSc in Chemistry from California Institute of Technology in 1989 and MA in Organic Chemistry from Harvard University in 1996. After spending a number of years in expanding his drug discovery expertise at Biogen, ARIAD Pharmaceuticals (currently Takeda Oncology), Tanabe Research Labs, Arena Pharmaceuticals and Ambit Biosciences, he spent almost 15 years at Novartis (GNF) in San Diego helping to bring to preclinical stage a number of projects for treatment of diabetes, cancer, auto-immune diseases, and cystic fibrosis. Since leaving Novartis, Mihai has worked first with Plexium, and currently with 1859, Inc. in developing technology platforms that could speed up and expand the drug-discovery process, including efforts to modulate the activity of biological targets that have been proven difficult to address.
Mihai is a coauthor of over 25 patents and almost 20 peer-reviewed articles.
Section ID:
Class type:
This course is entirely web-based and to be completed asynchronously between the published course start and end dates. Synchronous attendance is NOT required.
You will have access to your online course on the published start date OR 1 business day after your enrollment is confirmed if you enroll on or after the published start date.
Textbooks:
Tietz Fundamentals fo Clinical Chemistry and Molecular Diagnostics 8th
by Nader Rifai
ISBN / ASIN: 9780323530446
You may purchase textbooks via the UC San Diego Bookstore.
Policies:
- No refunds after: 2/10/2025
Schedule:
Instructor:
Mihai Azimioara
Mihai D. Azimioara is currently Senior Staff Scientist in the Chemistry Department at 1859, Inc. in San Diego. He has more than 25 years of experience in drug discovery.
He received his BSc in Chemistry from California Institute of Technology in 1989 and MA in Organic Chemistry from Harvard University in 1996. After spending a number of years in expanding his drug discovery expertise at Biogen, ARIAD Pharmaceuticals (currently Takeda Oncology), Tanabe Research Labs, Arena Pharmaceuticals and Ambit Biosciences, he spent almost 15 years at Novartis (GNF) in San Diego helping to bring to preclinical stage a number of projects for treatment of diabetes, cancer, auto-immune diseases, and cystic fibrosis. Since leaving Novartis, Mihai has worked first with Plexium, and currently with 1859, Inc. in developing technology platforms that could speed up and expand the drug-discovery process, including efforts to modulate the activity of biological targets that have been proven difficult to address.
Mihai is a coauthor of over 25 patents and almost 20 peer-reviewed articles.
Section ID:
Class type:
This course is entirely web-based and to be completed asynchronously between the published course start and end dates. Synchronous attendance is NOT required.
You will have access to your online course on the published start date OR 1 business day after your enrollment is confirmed if you enroll on or after the published start date.
Textbooks:
Tietz Fundamentals fo Clinical Chemistry and Molecular Diagnostics 8th
by Nader Rifai
ISBN / ASIN: 9780323530446
You may purchase textbooks via the UC San Diego Bookstore.
Policies:
- No refunds after: 3/3/2025
Schedule:
Instructor:
Mihai Azimioara
Mihai D. Azimioara is currently Senior Staff Scientist in the Chemistry Department at 1859, Inc. in San Diego. He has more than 25 years of experience in drug discovery.
He received his BSc in Chemistry from California Institute of Technology in 1989 and MA in Organic Chemistry from Harvard University in 1996. After spending a number of years in expanding his drug discovery expertise at Biogen, ARIAD Pharmaceuticals (currently Takeda Oncology), Tanabe Research Labs, Arena Pharmaceuticals and Ambit Biosciences, he spent almost 15 years at Novartis (GNF) in San Diego helping to bring to preclinical stage a number of projects for treatment of diabetes, cancer, auto-immune diseases, and cystic fibrosis. Since leaving Novartis, Mihai has worked first with Plexium, and currently with 1859, Inc. in developing technology platforms that could speed up and expand the drug-discovery process, including efforts to modulate the activity of biological targets that have been proven difficult to address.
Mihai is a coauthor of over 25 patents and almost 20 peer-reviewed articles.